ClinicalTrials.gg
TerminatedNCT04251533EPIK-B3Updated Sep 10, 2026Results posted

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

A Phase 3 interventional study of alpelisib and placebo in Triple Negative Breast Neoplasms, sponsored by Novartis Pharmaceuticals. Terminated at 78 sites in 30 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Triple Negative Breast Neoplasms by Novartis — 4 open to participants now, 6 under way, none of them phase 3. Triple Negative Breast Neoplasms · Novartis.

Enrollment
11th of 22
137 · median 132
Started
2020
the only one that year
Phase 3
Only one
of the 22
Registered
16th of 22
by date

Among the 22 studies in Triple Negative Breast Neoplasms by Novartis, this one is the 11th largest by enrollment, is the only one that started in 2020, is the only one in phase 3, and was the 16th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

4 of the 22 studies in Triple Negative Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Triple Negative Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)

Read the detailed description

The recruitment of Part A was halted on 11-Nov-2022 due to slow recruitment. Since Part B1 did not meet its primary objective for confirmed overall response rate, the Part B2 was not initiated, and the recruitment was halted for the entire study.

Upon confirming either PIK3CA mutation and/or PTEN loss status, advanced TNBC participants meeting all other eligibility criteria were assigned to either Part A (PIK3CA mutation regardless of PTEN loss) or Part B1 (PTEN loss with PIK3CA unknown or non-mutant).

In Part A, participants were randomized a 1:1 to receive either:

  • alpelisib 300 mg daily orally + nab-paclitaxel 100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle or
  • placebo + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.

In Part B1, participants received alpelisib 300 mg daily orally + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • Triple Negative Breast Cancer
  • alpelisib
  • BYL719
  • nab-paclitaxel
  • PIK3CA mutation
  • PTEN loss
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed diagnosis of advanced (loco-regionally recurrent and not amenable to curative therapy), or (stage IV) TNBC
  • Participant has either a per 1.1 criteria or, if no measurable disease is present, then at least one predominantly lytic bone lesion or mixed lytic-blastic bone lesion with identifiable soft tissue component (that can be evaluated by CT/MRI) must be present. Part B1: Participants must have measurable disease
  • Participant has adequate tumor tissue to identify the PIK3CA mutation status (either carrying a mutation or without a mutation) and the PTEN loss status; both of which will determine whether the subject can be allocated to Part A - PIK3CA mutation regardless of PTEN status; or to Part B1 - PTEN loss or to Part B2 - PTEN loss without a PIK3CA mutation
  • Participant has an (ECOG) performance status of 0 or 1
  • Participant has received no more than one for metastatic disease
  • Participant has adequate bone marrow and organ function

Exclusion criteria

Exclusion Criteria:

  • Participant has received prior treatment with any PI3K, mTOR or AKT inhibitor
  • Participant has a known to alpelisib, nab-paclitaxel or to any of their
  • Participant has not recovered from all toxicities related to prior anticancer therapies to version 4.03 Grade ≤1; with the exception of alopecia
  • Participant has central nervous system (CNS) involvement which was not previously treated and/or was newly detected at screening
  • Participant with an established diagnosis of diabetes mellitus type I or uncontrolled type II based on Fasting Plasma Glucose and
  • Participant has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) based on investigator discretion
  • Participant has a history of acute pancreatitis within 1 year prior to screening or past medical history of chronic pancreatitis
  • Participant has currently documented pneumonitis/interstitial lung disease
  • Participant has a history of severe cutaneous reactions, such as Steven-Johnson Syndrome (SJS), erythema multiforme (EM),Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Syndrome (DRESS)
  • Participant with unresolved osteonecrosis of the jaw
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Part A: alpelisib + nab-paclitaxel

    Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle

    Drug: alpelisib · Drug: nab-paclitaxel

  • Placebo comparator
    Part A: placebo + nab-paclitaxel

    Participants received placebo + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.

    Drug: placebo · Drug: nab-paclitaxel

  • Experimental
    Part B1: alpelisib + nab-paclitaxel

    Participants received alpelisib 300 mg orally + nab-paclitaxel 100 mg/m\^2 IV on Days 1, 8, and 15 of each 28-day cycle.

    Drug: alpelisib · Drug: nab-paclitaxel

Interventions

  • 300 mg orally, once per day (QD), tablets

    Also known as: BYL719

  • Drugplacebo

    300 mg orally, once per day (QD), tablets

    Also known as: alpelisib-matching placebo

  • 100 mg/m\^2 IV infusion, once per day (QD)

    Also known as: abraxane

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Investigator Assessment in Study Part A

    PFS was defined as time from the date of randomization to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  2. Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1

    ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 6 months

Secondary outcomes

  1. Overall Survival in Study Part A

    Overall survival is defined as the time from date of randomization to date of death due to any cause.

    Time frame: Up to 66 months

  2. Overall Response Rate (ORR) With Confirmed Response in Study Part A

    ORR with confirmed response was the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  3. Clinical Benefit Rate (CBR) With Confirmed Response in Study Part A

    Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  4. Clinical Benefit Rate (CBR) With Confirmed Response in Study Part B1

    Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

    Time frame: Up to 6 months

  5. Time to Response (TTR) in Study Part A

    Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  6. Time to Response (TTR) in Study Part B1

    Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response was used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to 6 months

  7. Duration of Response (DOR) With Confirmed Response in Study Part A

    Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  8. Duration of Response (DOR) With Confirmed Response in Study Part B1

    Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 20 months

  9. Overall Survival in Study Part B1

    Overall survival for Part B1 was defined as the number of participants who were alive at the end of the post-treatment period.

    Time frame: Up to approximately 26 months.

  10. Progression-free Survival (PFS) Per Investigator Assessment in Study Part B1

    PFS was defined as time from the date of enrolment to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.

    Time frame: Up to 6 months

  11. PFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A

    PFS in participants with PIK3CA mutation as measured in ctDNA. PFS was defined as time from the date of randomization to the date of the first documented progression or death due to any cause.

    Time frame: Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months

  12. Post-Hoc: All Collected Deaths

    On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of study treatment. Post-treatment survival follow-up deaths were collected from Day 31 after last dose of study medication to the data cut-off date.

    Time frame: On-treatment deaths: Up to approximately 28 months (Part A) or approximately 17 months (Part B1). Post-treatment survival follow-up deaths: Up to approximately 7 additional months (Part A) or approximately 9 additional months (Part B1).

07

Results

Posted Jul 31, 2024

Participant flow

Participant flow — Overall Study
MilestonePart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxelPart B1: Alpelisib + Nab-paclitaxel
Started525035
Completed8144
Not completed443631
Withdrew: Progressive disease332922
Withdrew: Death513
Withdrew: Physician decision324
Withdrew: Participant decision131
Withdrew: Adverse event211

Outcome measures

PrimaryProgression-free Survival (PFS) Per Investigator Assessment in Study Part A

PFS was defined as time from the date of randomization to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Median · months
Progression-free Survival (PFS) Per Investigator Assessment in Study Part A
monthsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
Progression-free Survival (PFS) Per Investigator Assessment in Study Part A7.2 (3.71 to 8.57)5.6 (3.75 to 12.68)
Statistical analysis
  • Part A: Alpelisib + Nab-paclitaxel vs Part A: Placebo + Nab-paclitaxel · Regression, Cox · Hazard ratio (hr): 1.49 · 95% CI 0.92 to 2.41
PrimaryOverall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1

ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B1
percentage of participantsPart B1: Alpelisib + Nab-paclitaxel
Overall Response Rate (ORR) Based on Local Radiology Assessments in Participants With Measurable Disease at Baseline in Study Part B114.3 (4.8 to 30.3)
SecondaryOverall Survival in Study Part A

Overall survival is defined as the time from date of randomization to date of death due to any cause.

Time frame:
Up to 66 months

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR) With Confirmed Response in Study Part A

ORR with confirmed response was the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as per local review and according to RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until progressive disease (PD)/recurrence. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) With Confirmed Response in Study Part A
percentage of participantsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
Overall Response Rate (ORR) With Confirmed Response in Study Part A40.4 (27.0 to 54.9)34.0 (21.2 to 48.8)
SecondaryClinical Benefit Rate (CBR) With Confirmed Response in Study Part A

Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part A
percentage of participantsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part A50.0 (35.8 to 64.2)44.0 (30.0 to 58.7)
SecondaryClinical Benefit Rate (CBR) With Confirmed Response in Study Part B1

Clinical benefit rate (CBR) was defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part B1
percentage of participantsPart B1: Alpelisib + Nab-paclitaxel
Clinical Benefit Rate (CBR) With Confirmed Response in Study Part B125.7 (12.5 to 43.3)
SecondaryTime to Response (TTR) in Study Part A

Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Median · months
Time to Response (TTR) in Study Part A
monthsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
Time to Response (TTR) in Study Part ANA (4.14 to NA)NA (NA to NA)
SecondaryTime to Response (TTR) in Study Part B1

Time to response (TTR) was defined as the time from the date of randomization/enrolment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response was used, not date of confirmation). CR and PR were based on tumor response data as per local review and according to RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to 6 months
Reported as:
Median · months
Time to Response (TTR) in Study Part B1
monthsPart B1: Alpelisib + Nab-paclitaxel
Time to Response (TTR) in Study Part B1NA (NA to NA)
SecondaryDuration of Response (DOR) With Confirmed Response in Study Part A

Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Median · months
Duration of Response (DOR) With Confirmed Response in Study Part A
monthsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
Duration of Response (DOR) With Confirmed Response in Study Part A7.39 (5.59 to 9.53)NA (10.55 to NA)
SecondaryDuration of Response (DOR) With Confirmed Response in Study Part B1

Duration of response (DOR) with confirmed response only applied to participants whose best overall response (BOR) was confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date was the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date was defined as the date of the first documented progressive disease (PD) or death due to underlying cancer. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 20 months
Reported as:
Median · months
Duration of Response (DOR) With Confirmed Response in Study Part B1
monthsPart B1: Alpelisib + Nab-paclitaxel
Duration of Response (DOR) With Confirmed Response in Study Part B111.04 (7.46 to NA)
SecondaryOverall Survival in Study Part B1

Overall survival for Part B1 was defined as the number of participants who were alive at the end of the post-treatment period.

Time frame:
Up to approximately 26 months.
Reported as:
Count of participants · Participants
Overall Survival in Study Part B1
ParticipantsPart B1: Alpelisib + Nab-paclitaxelEdit
Overall Survival in Study Part B121
SecondaryProgression-free Survival (PFS) Per Investigator Assessment in Study Part B1

PFS was defined as time from the date of enrolment to the date of the first documented progressive disease (PD) or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. PD=At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm\^2. PFS was censored at the date of the last adequate tumor assessment, if no PFS event was observed prior to the analysis cut-off date.

Time frame:
Up to 6 months
Reported as:
Median · months
Progression-free Survival (PFS) Per Investigator Assessment in Study Part B1
monthsPart B1: Alpelisib + Nab-paclitaxel
Progression-free Survival (PFS) Per Investigator Assessment in Study Part B13.71 (3.15 to 5.88)
SecondaryPFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A

PFS in participants with PIK3CA mutation as measured in ctDNA. PFS was defined as time from the date of randomization to the date of the first documented progression or death due to any cause.

Time frame:
Once all participants have completed at least 6 months of study treatment or have discontinued from study treatment, up to 35 months
Reported as:
Median · months
PFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A
monthsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxel
PFS Based on Local Radiology Assessments Using RECIST 1.1 Criteria for Participants by PIK3CA Mutation Status Measured in Baseline Circulating Tumor Deoxyribonucleic Acid (ctDNA) in Study Part A7.5 (3.58 to 9.17)3.5 (1.77 to 5.85)
SecondaryPost-Hoc: All Collected Deaths

On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of study treatment. Post-treatment survival follow-up deaths were collected from Day 31 after last dose of study medication to the data cut-off date.

Time frame:
On-treatment deaths: Up to approximately 28 months (Part A) or approximately 17 months (Part B1). Post-treatment survival follow-up deaths: Up to approximately 7 additional months (Part A) or approximately 9 additional months (Part B1).
Reported as:
Count of participants · Participants
Post-Hoc: All Collected Deaths
ParticipantsPart A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxelPart B1: Alpelisib + Nab-paclitaxelEdit
On-treatment deaths663
Post-treatment survival follow-up deaths191411
All deaths252014

Adverse events

Collected over Adverse events were collected up to approximately 28 months (Part A) or up to approximately 17 months (Part B1). Deaths were collected in the post-treatment survival follow-up from 31 days after last dose of study medication until the data cut-off date, up to approximately 7 additional months (Part A) or approximately 9 additional months (Part B1). These were not considered AEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Alpelisib + Nab-paclitaxelEdit6/52 (11.5%)22/52 (42.3%)51/52 (98.1%)
Part A: Placebo + Nab-paclitaxelEdit6/50 (12%)15/50 (30%)47/50 (94%)
Part B1: Alpelisib + Nab-paclitaxelEdit3/35 (8.6%)14/35 (40%)34/35 (97.1%)
Part A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)19/46 (41.3%)——
Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up)14/44 (31.8%)——
Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)11/32 (34.4%)——
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventPart A: Alpelisib + Nab-paclitaxelEditPart A: Placebo + Nab-paclitaxelEditPart B1: Alpelisib + Nab-paclitaxelEditPart A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up)Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)
Pleural effusionRespiratory, thoracic and mediastinal disorders4/521/501/35———
StomatitisGastrointestinal disorders3/520/500/35———
DiarrhoeaGastrointestinal disorders1/520/502/35———
DyspnoeaRespiratory, thoracic and mediastinal disorders0/522/500/35———
PyrexiaGeneral disorders2/521/500/35———
PneumoniaInfections and infestations2/520/501/35———
HyperglycaemiaMetabolism and nutrition disorders2/520/500/35———
Back painMusculoskeletal and connective tissue disorders2/521/501/35———
Abdominal painGastrointestinal disorders0/520/501/35———
HaemorrhoidsGastrointestinal disorders1/520/501/35———
Most frequent other events
Showing 10 of 84
Most frequent other events
EventPart A: Alpelisib + Nab-paclitaxelEditPart A: Placebo + Nab-paclitaxelEditPart B1: Alpelisib + Nab-paclitaxelEditPart A: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)Part A: Placebo + Nab-paclitaxel (Post-treatment Survival Follow-up)Part B1: Alpelisib + Nab-paclitaxel (Post-treatment Survival Follow-up)
HyperglycaemiaMetabolism and nutrition disorders38/528/5019/35———
DiarrhoeaGastrointestinal disorders33/5211/5021/35———
NauseaGastrointestinal disorders20/5212/5017/35———
AnaemiaBlood and lymphatic system disorders25/5222/5011/35———
Weight decreasedInvestigations24/525/5013/35———
AlopeciaSkin and subcutaneous tissue disorders13/5214/508/35———
NeutropeniaBlood and lymphatic system disorders10/5213/508/35———
RashSkin and subcutaneous tissue disorders13/5213/503/35———
FatigueGeneral disorders12/5210/509/35———
StomatitisGastrointestinal disorders13/522/507/35———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxelPart B1: Alpelisib + Nab-paclitaxelTotal
Mean56.8 ± 9.7659.1 ± 11.3448.4 ± 12.2155.5 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxelPart B1: Alpelisib + Nab-paclitaxelTotal
Female524935136
Male0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Alpelisib + Nab-paclitaxelPart A: Placebo + Nab-paclitaxelPart B1: Alpelisib + Nab-paclitaxelTotal
White32302385
Asian17191046
Multiple1102
Black Or African American1012
American Indian or Alaska Native0011
Unknown1001
08

Study locations

78 sites
  • University of California LA
    Los Angeles, California 90095, United States
  • Hematology and Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Park Nicollet Institute
    Saint Louis Park, Minnesota 55416, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Novartis Investigative Site
    CABA, C1113AAE, Argentina
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Leoben, 8700, Austria
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01317-002, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04014-002, Brazil
  • Novartis Investigative Site
    Plovdiv, 4004, Bulgaria
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050011, China
  • Novartis Investigative Site
    Changsha, Hunan 410013, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330009, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Shengyang, Liaoning 110042, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Dalian, 116000, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Tianjin, 300480, China
  • Novartis Investigative Site
    Bogotá, 110221, Colombia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Saint-Cloud, Hauts De Seine 92210, France
  • Novartis Investigative Site
    Angers, 49055, France
  • Novartis Investigative Site
    Saint-Herblain, 44805, France
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Essen, 45136, Germany
  • Novartis Investigative Site
    Budapest, 1134, Hungary
  • Novartis Investigative Site
    Faridabad, Haryana 121001, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400056, India
  • Novartis Investigative Site
    Vellore, Tamil Nadu 632004, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500034, India
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Meldola, FC 47014, Italy
  • Novartis Investigative Site
    Roma, RM 00128, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Petaling Jaya, Selangor 46050, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Oslo, 0407, Norway
  • Novartis Investigative Site
    Trujillo, La Libertad 13011, Peru
  • Novartis Investigative Site
    Gdynia, 81-519, Poland
  • Novartis Investigative Site
    Opole, 45-061, Poland
  • Novartis Investigative Site
    Poznan, 61-485, Poland
  • Novartis Investigative Site
    Arkhangelsk, 163045, Russia
  • Novartis Investigative Site
    Chelyabinsk, 454048, Russia
  • Novartis Investigative Site
    Moscow, 117997, Russia
  • Novartis Investigative Site
    Moscow, 123056, Russia
  • Novartis Investigative Site
    Saint Petersburg, 196603, Russia
  • Novartis Investigative Site
    Bratislava, 812 50, Slovakia
  • Novartis Investigative Site
    Bratislava, 83310, Slovakia
  • Novartis Investigative Site
    Košice, 041 91, Slovakia
  • Novartis Investigative Site
    Ljubljana, 1000, Slovenia
  • Novartis Investigative Site
    Port Elizabeth, Western Cape 6045, South Africa
  • Novartis Investigative Site
    Johannesburg, 2196, South Africa
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Palma, Balearic Islands 07120, Spain
  • Novartis Investigative Site
    Badajoz, Extremadura 06080, Spain
  • Novartis Investigative Site
    Alicante, 03010, Spain
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 10449, Taiwan
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Kadikoy 34722, Turkey (Türkiye)
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in May 2023, 35 months.

Results were first posted in Jul 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2020
First posted
Feb 5, 2020
StartActual
Jun 8, 2020
Primary completionActual
May 31, 2023
CompletionActual
Feb 5, 2026
Results first posted
Jul 31, 2024
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04251533
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jun 8, 2020
Primary completion
May 31, 2023
Completion
Feb 5, 2026
Results posted
Jul 31, 2024
Last update
Sep 10, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion